Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of Rina-S (PRO1184) in locally advanced and/or metastatic solid tumors
CTR20230813Phase 2Active
- Sponsor
- ProfoundBio
- Start
- Jun 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rinatabart sesutecan in Nonhematologic neoplasms, endometrial cancer (EC), ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by ProfoundBio. Started Jun 2023; status: active.
02
Drugs
rinatabart sesutecan
03
Conditions
Nonhematologic neoplasmsendometrial cancer (EC)ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20230813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230813.